Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 10:04 PM ET

Life Sciences Tools and Services

Company Overview of Syros Pharmaceuticals, Inc.

Company Overview

Syros Pharmaceuticals, Inc., a life sciences company, focuses on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. The company was founded in 2011 and is based in Watertown, Massachusetts.

480 Arsenal Street

Suite 130

Watertown, MA 02472

United States

Founded in 2011

Phone:

617-744-1340

Fax:

617-744-1377

Key Executives for Syros Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 54
Scientific Founder, Director and Member of Scientific Advisory Board
Age: 61
Scientific Founder, Director and Member of Scientific Advisory Board
Age: 42
Scientific Founder and Member of Scientific Advisory Board
Chief Financial Officer and Chief Product Officer
Compensation as of Fiscal Year 2015.

Syros Pharmaceuticals, Inc. Key Developments

Syros Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 01:00 PM

Syros Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 01:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Jorge Conde, Chief Financial Officer and Chief Product Officer.

Syros Pharmaceuticals Augments Senior Leadership Team

Syros Pharmaceuticals announced the addition of three senior members to the company. Jonathan Garen joins the company as Chief Business Officer; Christopher Roberts, Ph.D., as Vice President of Chemistry and Early Development; and Colleen DeSimone as Vice President of Finance and Controller. Jonathan Garen joins Syros from Actavis, where he served as Assistant Vice President of Corporate Development following Actavis’ acquisition of Forest Laboratories in 2014. Prior to the acquisition, he was Assistant Vice President of Business Development at Forest where he worked for more than 10 years and closed 11 deals – including three products currently on the market. Prior to Forest, Jon was a Director in the Global Licensing department at Pharmacia Corporation, and before that he was a founder and Vice President of TechEx, an online exchange service matching licensing opportunities from academic research institutions with potential life sciences licensors and investors. Christopher Roberts joins Syros from GlaxoSmithKline, where he held several leadership positions, most recently as Vice President of the AntiViral Discovery Performance Unit as part of the global GSK Infectious Disease Therapy Unit. He also served as Director of Medicinal Chemistry in the HCV Discovery Performance Unit, and worked as an Early Clinical Development Leader throughout his time at GSK. Before that, Chris held several positions in Medicinal Chemistry at Genelabs Technologies prior to its acquisition by GSK in 2009. He has led multiple assets from discovery into clinical development, with two establishing successful clinical proof-of-concept outcomes. Chris holds a Ph.D. in Organic Chemistry from the University of California, Riverside, and a B.A. in Chemistry from Whitworth College. Colleen DeSimone joins Syros from Takeda Pharmaceuticals where she served as Senior Director, Finance and Controller, responsible for all aspects of financial reporting, accounting and internal controls of Takeda’s oncology business unit in Cambridge, MA. She held several financial and operational positions at Millennium Pharmaceuticals before its acquisition by Takeda in 2008.

Syros Pharmaceuticals Announces New Research Published on Role of Cell Signaling Pathways in Gene Control

Syros Pharmaceuticals announced the publication of a study that demonstrated how gene control components, known as super-enhancers, act as functional units that concentrate multiple signaling pathways at key genes and can coordinate transcriptional activity. This work demonstrates how these gene control components provide a platform for signaling pathways to regulate key genes that control cell identity in normal cells and in cancer.

Similar Private Companies By Industry

Company Name Region
Formatech, Inc. United States
DataStat, Inc. United States
WuXi AppTec, Inc. United States
HemoGenix, Inc. United States
GeneHarbor Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 9, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Syros Pharmaceuticals, Inc., please visit www.syros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.